Publicaciones en colaboración con investigadores/as de Hospital Universitario La Paz (88)

2023

  1. Adult T-cell leukemia/lymphoma in HTLV-1 non-endemic regions

    Journal of Clinical Virology, Vol. 167

2022

  1. Trends in hospitalizations and deaths in HIV-infected patients in Spain over two decades

    AIDS, Vol. 36, Núm. 2, pp. 249-256

2020

  1. Advances in hepatitis B therapeutics

    Therapeutic Advances in Infectious Disease, Vol. 7

  2. COVID-19 comes 40 years after aids – Any lesson?

    AIDS Reviews, Vol. 22, Núm. 1, pp. 1-15

  3. Covid-19 comes 40 years after aids – any lesson?

    AIDS Reviews, Vol. 22, Núm. 2, pp. 63-77

  4. Hospital admissions in individuals with HTLV-1 infection in Spain

    AIDS, Vol. 34, Núm. 7, pp. 1019-1027

2019

  1. Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain

    Journal of Antimicrobial Chemotherapy, Vol. 74, Núm. 5, pp. 1357-1362

  2. Clinical presentation of individuals with human T-cell leukemia virus type-1 infection in Spain

    Open Forum Infectious Diseases, Vol. 6, Núm. 2

2018

  1. Decline and changing profile of hepatitis delta among injection drug users in Spain

    Antiviral Therapy, Vol. 23, Núm. 1, pp. 87-90

  2. Prevalence and incidence of hepatitis delta in patients with chronic hepatitis B in Spain

    European Journal of Gastroenterology and Hepatology, Vol. 30, Núm. 9, pp. 1060-1062

  3. Short article: Hepatitis delta in patients with resolved hepatitis B virus infection

    European Journal of Gastroenterology and Hepatology, Vol. 30, Núm. 9, pp. 1063-1065

  4. Treatment and prevention of HIV infection with long-acting antiretrovirals

    Expert Review of Clinical Pharmacology, Vol. 11, Núm. 5, pp. 507-517

2017

  1. Antiretroviral treatment of HIV-2 infection

    Future Virology, Vol. 12, Núm. 8, pp. 461-472

  2. Drug interactions in HIV-infected patients treated for hepatitis C

    Expert Opinion on Drug Metabolism and Toxicology, Vol. 13, Núm. 8, pp. 807-816

  3. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 7, pp. 2083-2088

  4. Dual antiretroviral therapy for HIV infection

    Expert Opinion on Drug Safety, Vol. 16, Núm. 8, pp. 923-932

  5. Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C

    Expert Opinion on Drug Metabolism and Toxicology, Vol. 13, Núm. 9, pp. 1015-1022

  6. HIV type 2 epidemic in Spain: Challenges and missing opportunities

    AIDS, Vol. 31, Núm. 10, pp. 1353-1364

  7. Human T-Lymphotropic Virus Infection in Hepatitis C Virus-Antibody Positive Patients in Spain

    AIDS Research and Human Retroviruses, Vol. 33, Núm. 10, pp. 1013-1017

  8. Human T-lymphotropic virus type 1 infection and disease in Spain

    AIDS, Vol. 31, Núm. 12, pp. 1653-1663